MentalHealthDaily

Comparison of Brexipiprazole vs. Aripiprazole for Treatment-Resistant Depression (2024 Study)

by GLOOM

Antidepressant-resistant major depressive disorder (AR-MDD) poses significant challenges in psychiatric treatment. Antipsychotics like aripiprazole (ARI) and brexpiprazole (BRE) have emerged as effective adjunct therapies that may be more tolerable than older antipsychotics. Highlights: Both Brexipiprazole and Aripiprazole demonstrated better efficacy than placebo in treating AR-MDD in Japanese patients. Brexipiprazole showed a higher discontinuation rate due …

Analyzing Brain Connectivity with Advanced Neuroimaging to Treat Major Depression (2023 Research)

by GLOOM

Depression, a leading cause of disability globally, presents a myriad of treatment challenges. Recent advancements in neuroimaging, particularly in understanding brain connectivity, offer a new lens through which we can view and potentially enhance the treatment of Major Depressive Disorder (MDD). Highlights: Major Depressive Disorder (MDD) affects millions worldwide, with traditional treatments showing varied success …

Neuromodulation Therapies to Treat Neuroinflammation in Anxiety & Depression (2023 Research)

by GLOOM

The intersection of neuromodulation, neuroinflammation, and their roles in mood disorders like anxiety and depression represents a significant stride in mental health research. This complex interplay underscores the potential of novel therapeutic strategies targeting the brain’s inflammatory pathways, offering new hope for effective management of these pervasive conditions. Highlights: Link Between Neuroinflammation and Mood Disorders: …

Low Dose LSD for Depression Treatment: Preliminary Efficacy (2023 Study)

by GLOOM

Recent research exploring the use of low doses of LSD (Lysergic acid diethylamide) in treating depression marks a significant shift in the psychiatric landscape. This innovative approach seeks to understand and harness the potential therapeutic benefits of psychedelics, which were once stigmatized and largely overlooked in clinical settings. Highlights: Study Design: The research employed a …

Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for Rapid Treatment of Suicidal Depression (2023 Study)

by GLOOM

Major depressive disorder (MDD) is a critical public health issue, particularly due to the high risk of suicide associated with it. Traditional treatments often take weeks to show effects and sometimes increase suicide risk in the early phases of therapy. However, a new approach, the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), is showing promise in …

Psychedelics for Depression: Targeting the 5-HT2A Receptor & Beyond (2023 Study)

by GLOOM

The quest for effective treatments for Major Depressive Disorder (MDD) has taken a revolutionary turn with the exploration of psychedelic compounds. Recent research has evaluated the potential of substances like psilocybin and lisuride, offering new hope for patients unresponsive to traditional antidepressants. Highlights: Traditional Limitations: Standard antidepressants often fail to provide relief for 30% of …

Gray Matter Abnormalities in Major Depression & Social Anxiety (2023 Analysis)

by GLOOM

Major depressive disorder (MDD) and social anxiety disorder (SAD) are two of the most prevalent mental health issues facing society today. They often occur together, challenging both patients and healthcare providers. Recent neuroimaging studies have begun to shed light on the unique and overlapping characteristics of these disorders, offering new insights into their complex neurobiology. …